CellCure Neurosciences

Company Overview

Snapshot

Founded in November 2005, CellCure Neurosciences operates with 11–50 employees. The company has raised $21.79 million across 9 funding rounds from 3 investors. In December 2021, CellCure Neurosciences established an exclusive worldwide collaboration with Genentech for the development and commercialization of its OpRegen® RPE Cell Therapy.

Business overview

CellCure Neurosciences is a biotechnology company focused on developing cell therapies for retinal and neural degenerative diseases. The company leverages human embryonic stem cells to manufacture retinal pigment epithelial (RPE) cells. Its primary product in development, OpRegen, is designed to treat the dry form of age-related macular degeneration (AMD), a condition affecting a significant portion of AMD patients for which there is currently no FDA-approved therapeutic. CellCure Neurosciences operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, and Biomaterials & Tissue Engineering.

Strategic signal

In December 2021, CellCure Neurosciences, a subsidiary of Lineage Cell Therapeutics, secured an exclusive worldwide collaboration with Genentech for the development and commercialization of its OpRegen® RPE Cell Therapy. This strategic partnership provides significant validation for CellCure's stem cell-derived RPE cell therapy platform and signals strong commercial potential and accelerated market access for its lead product in treating ocular disorders.

Company Intelligence Q&A

What was a significant recent strategic partnership for CellCure Neurosciences?

In December 2021, CellCure Neurosciences established an exclusive worldwide collaboration with Genentech for the development and commercialization of OpRegen® RPE Cell Therapy, targeting ocular disorders.

When did CellCure Neurosciences receive a grant from the Israel Innovation Authority?

In May 2019, CellCure Neurosciences was awarded a grant from the Israel Innovation Authority for the continued development of OpRegen®.

Which organization provided a grant to CellCure Neurosciences in May 2013?

In May 2013, CellCure Neurosciences received a grant from the Office of the Chief Scientist.

What was a key development for CellCure Neurosciences in February 2015?

In February 2015, CellCure Neurosciences provided an update on its product development and partnering activities, highlighting progress in its therapeutic programs.